npj Precision Oncology

Article	Citations
Defective homologous recombination and genomic instability predict increased responsiveness to carbon ion radiotherapy in pancreatic cancer	168
Relapse-free survival in a pediatric patient with recurrent EZH2-mutant melanoma treated with adjuvant tazemetostat	126
Pan-cancer analysis uncovered the prognostic and therapeutic value of disulfidptosis	114
Single cell analysis revealed SFRP2 cancer associated fibroblasts drive tumorigenesis in head and neck squamous cell carcinoma	92
Complement activation in tumor microenvironment after neoadjuvant therapy and its impact on pancreatic cancer outcomes	87
Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma	78
New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology	73
Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma	72
Methylation marks in blood DNA reveal breast cancer risk in patients fulfilling hereditary disease criteria	70
Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer	69
Immunological subtyping of salivary gland cancer identifies histological origin-specific tumor immune microenvironment	68
Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy	65
An automatic pipeline for temporal monitoring of radiotherapy-induced toxicities in head and neck cancer patients	63
Barriers and opportunities in pancreatic cancer immunotherapy	60
Integrins identified as potential prognostic markers in osteosarcoma through multi-omics and multi-dataset analysis	58
Copy-number alterations in cell-free DNA can be transient or harbingers of clonal hematopoiesis	56
High-throughput proteomics profiling-derived signature associated with chemotherapy response and survival for stage II/III colorectal cancer	55
Author Correction: An automated deep learning pipeline for EMVI classification and response prediction of rectal cancer using baseline MRI: a multi-centre study	54
Comparison of DNA methylation based classification models for precision diagnostics of central nervous system tumors	49
Development and validation of a gene expression-based Breast Cancer Purity Score	48
Deep learning for endometrial cancer subtyping and predicting tumor mutational burden from histopathological slides	47
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis	46
Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution	45
Towards precision radiation oncology: endocrine therapy response as a biomarker for personalization of breast radiotherapy	44
HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patients	44

DNA methylation at quantitative trait loci (mQTLs) varies with cell type and nonheritable factors and may improve breast cancer risk assessment	43
Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs	43
Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia	42
Grading of lung adenocarcinomas with simultaneous segmentation by artificial intelligence (GLASS-AI)	42
Biallelic EPCAM deletions induce tissue-specific DNA repair deficiency and cancer predisposition	38
Imaging and AI based chromatin biomarkers for diagnosis and therapy evaluation from liquid biopsies	38
Small extracellular vesicle PD-L1 in cancer: the knowns and unknowns	38
MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression	36
Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma	36
Precision medicine: affording the successes of science	36
Genome-wide analyses reveals an association between invasive urothelial carcinoma in the Shetland sheepdog and NIPAL1	36
Development and testing of a polygenic risk score for breast cancer aggressiveness	35
An automated deep learning pipeline for EMVI classification and response prediction of rectal cancer using baseline MRI: a multi-centre study	35
Learning generalizable AI models for multi-center histopathology image classification	35
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates	34
Targeting TYK2 alleviates Rab27A-induced malignant progression of non-small cell lung cancer via disrupting IFNα-TYK2-STAT-HSPA5 axis	34
Clonal gene signatures predict prognosis in mesothelioma and lung adenocarcinoma	34
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib	33
Deep learning-based detection and semi-quantitative model for spread through air spaces (STAS) in lung adenocarcinoma	33
Recurrent UBE3C-LRP5 translocations in head and neck cancer with therapeutic implications	32
Zebrafish tumour xenograft models: a prognostic approach to epithelial ovarian cancer	32
ELAVL2 loss promotes aggressive mesenchymal transition in glioblastoma	31
Comparative molecular profiling of pancreatic ductal adenocarcinoma of the head versus body and tail	30
Secrets of DNA-PKcs beyond DNA repair	29
Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting	29
Author Correction: Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs	29
Constitutional mismatch repair deficiency mimicking Lynch syndrome is associated with hypomorphic mismatch repair gene variants	29
CCL11/CCR3-dependent eosinophilia alleviates malignant pleural effusions and improves prognosis	28
Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition	28
PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL	28
Upregulated PrPC by HBx enhances NF-κB signal via liquid–liquid phase separation to advance liver cancer	28
Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities	27
Developing survival prediction models in colorectal cancer using epigenome-wide DNA methylation data from whole blood	27
Interferon signaling and ferroptosis in tumor immunology and therapy	27
Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors	27
Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers	26
Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer	26
A comprehensive analysis of minimally differentially methylated regions common to pediatric and adult solid tumors	25
Exploiting common patterns in diverse cancer types via multi-task learning	25
Deep learning for oncologic treatment outcomes and endpoints evaluation from CT scans in liver cancer	24
COL8A1 overexpression promotes glioma cell growth by activating focal adhesion kinase signaling cascade	24
Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitors	24
ACSL3 is an unfavorable prognostic marker in cholangiocarcinoma patients and confers ferroptosis resistance in cholangiocarcinoma cells	23
Longitudinal liquid biopsy predicts clinical benefit from immunotherapy in advanced non-small cell lung cancer	23
Characterization of shared neoantigens landscape in Mismatch Repair Deficient Endometrial Cancer	23
Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer	23
Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients	22
Multi-omics analysis deciphers intercellular communication regulating oxidative stress to promote oral squamous cell carcinoma progression	22
A DNA methylation-based liquid biopsy for triple-negative breast cancer	22
Patient-level proteomic network prediction by explainable artificial intelligence	22

Reduced penetrance BRCA1 and BRCA2 pathogenic variants in clinical germline genetic testing	22
Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition	21
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP	21
Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma	21
Author Correction: Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis	21
Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer	21
Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia	21
Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC	21
Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies	21
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer	20
The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition	20
Uncovering the genetic variation spectrum of colorectal polyposis from a multicentre cohort in China	20
Integrative whole slide image and spatial transcriptomics analysis with QuST and QuPath	20
Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusions	20
Prediction and analysis of tumor infiltrating lymphocytes across 28 cancers by TILScout using deep learning	20
Deep learning models in classifying primary bone tumors and bone infections based on radiographs	20
A protein-encoding CCDC7 circular RNA inhibits the progression of prostate cancer by up-regulating FLRT3	20
An appraisal of genetic testing for prostate cancer susceptibility	20
Targeting USP8 causes synthetic lethality through degradation of FGFR2 in ARID1A-deficient ovarian clear cell carcinoma	20
Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling	20
Single cell-spatial transcriptomics and bulk multi-omics analysis of heterogeneity and ecosystems in hepatocellular carcinoma	19
Tumor-associated macrophage clusters linked to immunotherapy in a pan-cancer census	19
Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer	19
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada	19
A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition	19
Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma	19
ARRB2 promotes cervical cancer progression via stabilizing CDC25A mRNA through m6A-IGF2BP1-dependent manner	18
BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape	18
Genome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (MCGI)	18
STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis	18
BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study	17
Spatial tumor immune microenvironment phenotypes in ovarian cancer	17
Predicting prognosis for epithelial ovarian cancer patients receiving bevacizumab treatment with CT-based deep learning	17
Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy	17
Precision immuno-oncology approach for four malignant tumors in siblings with constitutional mismatch repair deficiency syndrome	17
MRI transformer deep learning and radiomics for predicting IDH wild type TERT promoter mutant gliomas	17
Antibody-drug conjugates in lung cancer: dawn of a new era?	17
Functional combinatorial precision medicine for predicting and optimizing soft tissue sarcoma treatments	16
Multi-omics in immunotherapy research for HNSCC: present situation and future perspectives	16
DNA-based copy number analysis confirms genomic evolution of PDX models	16
Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity	16
Fast, accurate, and racially unbiased pan-cancer tumor-only variant calling with tabular machine learning	16
Single-cell transcriptome sequencing reveals spatial distribution of IL34+ cancer-associated fibroblasts in hepatocellular carcinoma tumor microenvironment	16
Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade	16
A framework for artificial intelligence in cancer research and precision oncology	16
Artificial intelligence in neuro-oncology: advances and challenges in brain tumor diagnosis, prognosis, and precision treatment	16
Multi-omics analysis reveals NNMT as a master metabolic regulator of metastasis in esophageal squamous cell carcinoma	16
Element-specific estimation of background mutation rates in whole cancer genomes through transfer learning	16
Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)	16
Taurine and proline promote lung tumour growth by co-regulating Azgp1/mTOR signalling pathway	16
All models are wrong and yours are useless: making clinical prediction models impactful for patients	15
A targetable OSGIN1 − AMPK − SLC2A3 axis controls the vulnerability of ovarian cancer to ferroptosis	15
A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures	15
A deep learning model for molecular label transfer that enables cancer cell identification from histopathology images	15
Immune-related cell death index and its application for hepatocellular carcinoma	15
piRNA28846 has the potential to be a novel RNA nucleic acid drug for ovarian cancer	15
A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer	15
Ancestry-associated co-alteration landscape of KRAS and EGFR-altered non-squamous NSCLC	15
Genomic landscape and comparative analysis of tissue and liquid-based NGS in Taiwanese anaplastic thyroid carcinoma	14
Longitudinal genomic profiling using liquid biopsies in metastatic nonsquamous NSCLC following first line immunotherapy	14
Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade	14
Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome	14
Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC	14
Development of a polygenic score predicting drug resistance and patient outcome in breast cancer	14
Prediction models of persistent taxane-induced peripheral neuropathy among breast cancer survivors using whole-exome sequencing	14
Home-run trials for rare cancers: giving the right drug(s) to the right patients at the right time and in the right place	14
Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM	14
Accurate identification of primary site in tumors of unknown origin (TUO) using DNA methylation	14
Genetic and epigenetic characterization of sarcoma stem cells across subtypes identifies EZH2 as a therapeutic target	14
FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes	14
Targeting Nrf2/PHKG2 axis to enhance radiosensitivity in NSCLC	13
Deep representation learning of tissue metabolome and computed tomography annotates NSCLC classification and prognosis	13
Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma	13
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab	13
Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy	13
BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors	13
Integration of pre-treatment computational radiomics, deep radiomics, and transcriptomics enhances soft-tissue sarcoma patient prognosis	13
Functional characterization of NPM1–TYK2 fusion oncogene	13
High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival	12
A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer	12

Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas	12
Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer	12
The deubiquitinase USP10 protects pancreatic cancer cells from endoplasmic reticulum stress	12
Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma	12
Ribosome biosynthesis and Hedgehog activity are cooperative actionable signaling mechanisms in breast cancer following radiotherapy	12
Large language models and multimodal foundation models for precision oncology	12
Deep learning on tertiary lymphoid structures in hematoxylin-eosin predicts cancer prognosis and immunotherapy response	12
Molecular disparities in colorectal cancers of White Americans, Alabama African Americans, and Oklahoma American Indians	12
Biology-aware mutation-based deep learning for outcome prediction of cancer immunotherapy with immune checkpoint inhibitors	12
Towards precision oncology discovery: four less known genes and their unknown interactions as highest-performed biomarkers for colorectal cancer	12
PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells	12
Genomic and epigenomic basis of breast invasive lobular carcinomas lacking CDH1 genetic alterations	12
Tumor heterogeneity and clinically invisible micrometastases in metastatic breast cancer—a call for enhanced surveillance strategies	12
IKKα promotes lung adenocarcinoma growth through ERK signaling activation via DARPP-32-mediated inhibition of PP1 activity	12
Single-cell landscape of bronchoalveolar immune cells in patients with immune checkpoint inhibitor-related pneumonitis	11
CAR-T cell therapy for the treatment of adult high-grade gliomas	11
Will polygenic risk scores for cancer ever be clinically useful?	11
Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality	11
Author Correction: An interpretable machine learning system for colorectal cancer diagnosis from pathology slides	11
Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity	11
Circulating tumor DNA is readily detectable among Ghanaian breast cancer patients supporting non-invasive cancer genomic studies in Africa	11
Molecular mechanisms and diagnostic model of glioma-related epilepsy	11
Mutational disparities in colorectal cancers of White Americans, Alabama African Americans, And Oklahoma American Indians	11
Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors	11